FOLH1抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Lncap cell, Primary antibody: P04675(FOLH1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04675(FOLH1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Folate hydrolase 1 (FOLH1), also known as prostate-specific membrane antigen (PSMA), is a transmembrane glycoprotein primarily expressed in prostate epithelial cells. It functions as a glutamate carboxypeptidase, hydrolyzing folate polyglutamates to release folate monoglutamates, which are critical for cellular metabolism. FOLH1 gained prominence as a biomarker due to its overexpression in prostate cancer cells, particularly in advanced or metastatic disease, making it a key target for diagnostic and therapeutic applications.

FOLH1 antibodies are immunological tools designed to detect or target this protein. In diagnostics, FOLH1 antibodies are used in immunohistochemistry (IHC) to assess prostate cancer progression and in imaging techniques (e.g., PSMA-PET scans) to locate metastatic lesions. Therapeutically, they form the basis of antibody-drug conjugates (ADCs) and radioligand therapies (e.g., ¹⁷⁷Lu-PSMA-617) that selectively deliver cytotoxic agents to FOLH1-positive cells.

Beyond prostate cancer, FOLH1 is explored in other cancers (e.g., glioblastoma) due to its vascular endothelial expression in tumor neovasculature. However, its physiological roles in the nervous system and small intestine remain less understood. Antibodies targeting FOLH1 must balance specificity to avoid off-target effects, given its low-level expression in healthy tissues. Ongoing research focuses on optimizing antibody engineering to enhance clinical efficacy and safety.